Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPPER: Durvalumab with Olaparib or Cediranib in Advanced Solid Tumors
NCT03851614Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Apr 2019
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, olaparib and cediranib in colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and leiomyosarcoma (LMS) (2 cohorts), sponsored by University Health Network. Primary endpoint: Changes in genomic and immune biomarkers at 3 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
durvalumabolaparibcediranib
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03851614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851614.